Comparative Pharmacology
Head-to-head clinical analysis: LATISSE versus MISOPROSTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATISSE versus MISOPROSTOL.
LATISSE vs MISOPROSTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It increases the growth of eyelashes by prolonging the anagen (growth) phase and increasing the number of hairs. The exact molecular mechanism is thought to involve binding to prostamide receptors, leading to modulation of intracellular signaling pathways that regulate hair follicle cycling.
Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.
One drop applied to the upper eyelid margin at the base of the eyelashes once daily using the provided sterile applicators.
200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.
None Documented
Clinical Note
moderateTiaprofenic acid + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Carprofen."
Clinical Note
moderateMesalazine + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Mesalazine."
Clinical Note
moderateBalsalazide + Misoprostol
None Documented
The terminal elimination half-life of bimatoprost in plasma is approximately 45 minutes (range 30-60 minutes) after topical ocular application in humans. This short half-life reflects rapid systemic clearance, but the drug's ocular hypotensive effect persists for 24 hours due to tissue binding.
2-3 hours for misoprostol acid (active metabolite); clinically, a short duration requires multiple daily dosing. In patients with renal impairment, half-life may be prolonged but not significantly clinically.
Primarily renal elimination of metabolites; less than 5% of unchanged bimatoprost is excreted in urine. Fecal excretion accounts for approximately 25% of the dose, predominantly as metabolites. Biliary excretion is minimal.
Primarily renal excretion of metabolites; ~80-90% of a radiolabeled dose is excreted in urine within 24 hours, with the remainder in feces. Misoprostol acid (active metabolite) undergoes further beta-oxidation and reduction; <1% excreted unchanged.
Category C
Category D/X
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Balsalazide."